认知功能疗法联合或不联合运动传感器生物反馈对比常规护理治疗慢性致残性下背痛(RESTORE):一项随机、对照、三臂、平行组、3期临床试验
RESTORE为在澳大利亚20家初级保健物理治疗诊所开展的随机、对照、三臂、平行组、3期试验,纳入492例慢性致残性下背痛成人,随机分为常规护理、仅认知功能疗法(CFT)、CFT联合生物反馈三组。13周时两种CFT干预在活动受限方面均优于常规护理(平均差-4.6),52周效应相似,且质量调整生命年更优、社会成本更低。
要点
- 13周时仅CFT组活动受限平均差-4.6(95%CI -5.9至-3.4),CFT联合生物反馈组-4.6(95%CI -5.8至-3.3),均优于常规护理。
- 52周时两种干预的效应量与13周相似。
- 两种干预的质量调整生命年优于常规护理,社会成本更低。
核心结论
- CFT可为慢性致残性下背痛患者带来大幅且持续改善,社会成本显著低于常规护理。
研究设计与样本
- RESTORE为在澳大利亚20家初级保健物理治疗诊所开展的随机、对照、三臂、平行组、3期试验。
- 2018年10月23日至2020年8月3日评估1011例患者,排除519例(51.3%)不合格者后随机分配492例(48.7%):仅CFT组164例(33%)、CFT联合生物反馈组163例(33%)、常规护理组165例(34%)。
- 纳入年龄≥18岁、下背痛持续超过3个月且至少中度疼痛相关体力活动受限的成人;排除严重脊柱病变、妨碍体力活动的疾病、妊娠或产后3个月内、英语读写不足、对低敏胶带过敏、3个月内计划手术或不愿前往试验地点者。
- 参与者按1:1:1通过中心化自适应方案随机分配;两种干预组在12周内接受最多7次治疗,并在26周接受1次强化治疗;物理治疗师和患者未设盲。
- 主要临床结局为13周时参与者自报的24分Roland Morris残疾问卷活动受限;主要经济结局为质量调整生命年(QALYs)。
主要发现
- 13周时活动受限(主要终点):仅CFT组平均差-4.6(95%CI -5.9至-3.4),CFT联合生物反馈组平均差-4.6(95%CI -5.8至-3.3),均优于常规护理。
- 52周时两种干预的效应量与13周相似。
- 两种干预的质量调整生命年均优于常规护理,且社会成本(直接和间接成本及生产力损失)大幅更低:仅CFT组-AU$5276(95%CI -10 529至-24),CFT联合生物反馈组-AU$8211(95%CI -12 923至-3500)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 物理治疗师和患者未设盲。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low back pain is the leading cause of years lived with disability globally, but most interventions have only short-lasting, small to moderate effects. Cognitive functional therapy (CFT) is an individualised approach that targets unhelpful pain-related cognitions, emotions, and behaviours that contribute to pain and disability. Movement sensor biofeedback might enhance treatment effects. We aimed to compare the effectiveness and economic efficiency of CFT, delivered with or without movement sensor biofeedback, with usual care for patients with chronic, disabling low back pain. METHODS: RESTORE was a randomised, controlled, three-arm, parallel group, phase 3 trial, done in 20 primary care physiotherapy clinics in Australia. We recruited adults (aged ≥18 years) with low back pain lasting more than 3 months with at least moderate pain-related physical activity limitation. Exclusion criteria were serious spinal pathology (eg, fracture, infection, or cancer), any medical condition that prevented being physically active, being pregnant or having given birth within the previous 3 months, inadequate English literacy for the study's questionnaires and instructions, a skin allergy to hypoallergenic tape adhesives, surgery scheduled within 3 months, or an unwillingness to travel to trial sites. Participants were randomly assigned (1:1:1) via a centralised adaptive schedule to usual care, CFT only, or CFT plus biofeedback. The primary clinical outcome was activity limitation at 13 weeks, self-reported by participants using the 24-point Roland Morris Disability Questionnaire. The primary economic outcome was quality-adjusted life-years (QALYs). Participants in both interventions received up to seven treatment sessions over 12 weeks plus a booster session at 26 weeks. Physiotherapists and patients were not masked. This trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12618001396213. FINDINGS: Between Oct 23, 2018 and Aug 3, 2020, we assessed 1011 patients for eligibility. After excluding 519 (51·3%) ineligible patients, we randomly assigned 492 (48·7%) participants; 164 (33%) to CFT only, 163 (33%) to CFT plus biofeedback, and 165 (34%) to usual care. Both interventions were more effective than usual care (CFT only mean difference -4·6 [95% CI -5·9 to -3·4] and CFT plus biofeedback mean difference -4·6 [-5·8 to -3·3]) for activity limitation at 13 weeks (primary endpoint). Effect sizes were similar at 52 weeks. Both interventions were also more effective than usual care for QALYs, and much less costly in terms of societal costs (direct and indirect costs and productivity losses; -AU$5276 [-10 529 to -24) and -8211 (-12 923 to -3500). INTERPRETATION: CFT can produce large and sustained improvements for people with chronic disabling low back pain at considerably lower societal cost than that of usual care. FUNDING: Australian National Health and Medical Research Council and Curtin University.
引用
- Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. Lancet. 2023. PMID: 37146623. doi:10.1016/S0140-6736(23)00441-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。